Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 245

1.

Glucose Control Using a Standard Versus an Enhanced Hybrid Closed Loop System: A Randomized Crossover Study.

Paldus B, Lee MH, Jones HM, McAuley SA, Horsburgh JC, Roem KL, Ward GM, MacIsaac RJ, Cohen N, Colman PG, Jenkins AJ, O'Neal DN.

Diabetes Technol Ther. 2019 Jan;21(1):56-58. doi: 10.1089/dia.2018.0279.

PMID:
30620641
2.

Viewpoints of adolescents with overweight and obesity attending lifestyle obesity treatment interventions: a qualitative systematic review.

Jones HM, Al-Khudairy L, Melendez-Torres GJ, Oyebode O.

Obes Rev. 2019 Jan;20(1):156-169. doi: 10.1111/obr.12771. Epub 2018 Oct 29.

PMID:
30375160
3.

Antibiotic prophylaxis and clinical outcomes among older adults with recurrent urinary tract infection: cohort study.

Ahmed H, Farewell D, Jones HM, Francis NA, Paranjothy S, Butler CC.

Age Ageing. 2018 Aug 28. doi: 10.1093/ageing/afy146. [Epub ahead of print]

PMID:
30165433
4.

Corrigendum to "A critical evaluation of venous thromboembolism risk assessment models used in patients with lower limb cast immobilization" [Foot Ankle Surg. 22 (3) (September 2016) 191-195].

Watson U, Hickey BA, Jones HM, Perera A.

Foot Ankle Surg. 2018 Jun;24(3):268. doi: 10.1016/j.fas.2018.04.006. Epub 2018 May 8. No abstract available.

PMID:
29933963
5.

Erratum: Atorvastatin exhibits anti-tumorigenic and anti-metastatic effects in ovarian cancer in vitro.

Jones HM, Fang Z, Sun W, Clark LH, Stine JE, Tran AQ, Sullivan SA, Gilliam TP, Zhou C, Bae-Jump VL.

Am J Cancer Res. 2018 May 1;8(5):915. eCollection 2018.

6.

Use of temperature to improve West Nile virus forecasts.

DeFelice NB, Schneider ZD, Little E, Barker C, Caillouet KA, Campbell SR, Damian D, Irwin P, Jones HMP, Townsend J, Shaman J.

PLoS Comput Biol. 2018 Mar 9;14(3):e1006047. doi: 10.1371/journal.pcbi.1006047. eCollection 2018 Mar.

7.

Atorvastatin exhibits anti-tumorigenic and anti-metastatic effects in ovarian cancer in vitro.

Jones HM, Fang Z, Sun W, Clark LH, Stine JE, Tran AQ, Sullivan SA, Gilliam TP, Zhou C, Bae-Jump VL.

Am J Cancer Res. 2017 Dec 1;7(12):2478-2490. eCollection 2017. Erratum in: Am J Cancer Res. 2018 May 01;8(5):915.

8.

Incidence and antibiotic prescribing for clinically diagnosed urinary tract infection in older adults in UK primary care, 2004-2014.

Ahmed H, Farewell D, Jones HM, Francis NA, Paranjothy S, Butler CC.

PLoS One. 2018 Jan 5;13(1):e0190521. doi: 10.1371/journal.pone.0190521. eCollection 2018.

9.

Phenformin has anti-tumorigenic effects in human ovarian cancer cells and in an orthotopic mouse model of serous ovarian cancer.

Jackson AL, Sun W, Kilgore J, Guo H, Fang Z, Yin Y, Jones HM, Gilliam TP, Zhou C, Bae-Jump VL.

Oncotarget. 2017 Oct 24;8(59):100113-100127. doi: 10.18632/oncotarget.22012. eCollection 2017 Nov 21.

10.

Using facial muscular movements to understand young children's emotion regulation and concurrent neural activation.

Grabell AS, Huppert TJ, Fishburn FA, Li Y, Jones HM, Wilett AE, Bemis LM, Perlman SB.

Dev Sci. 2018 Sep;21(5):e12628. doi: 10.1111/desc.12628. Epub 2017 Dec 11.

11.

Dual inhibition of glycolysis and glutaminolysis as a therapeutic strategy in the treatment of ovarian cancer.

Sun L, Yin Y, Clark LH, Sun W, Sullivan SA, Tran AQ, Han J, Zhang L, Guo H, Madugu E, Pan T, Jackson AL, Kilgore J, Jones HM, Gilliam TP, Zhou C, Bae-Jump VL.

Oncotarget. 2017 Jun 29;8(38):63551-63561. doi: 10.18632/oncotarget.18854. eCollection 2017 Sep 8.

12.

Whole grain cereals for the primary or secondary prevention of cardiovascular disease.

Kelly SA, Hartley L, Loveman E, Colquitt JL, Jones HM, Al-Khudairy L, Clar C, Germanò R, Lunn HR, Frost G, Rees K.

Cochrane Database Syst Rev. 2017 Aug 24;8:CD005051. doi: 10.1002/14651858.CD005051.pub3. Review.

13.

Glutaminase inhibitor compound 968 inhibits cell proliferation and sensitizes paclitaxel in ovarian cancer.

Yuan L, Sheng X, Clark LH, Zhang L, Guo H, Jones HM, Willson AK, Gehrig PA, Zhou C, Bae-Jump VL.

Am J Transl Res. 2016 Oct 15;8(10):4265-4277. eCollection 2016.

14.

Assessing the Impact of Tissue Target Concentration Data on Uncertainty in In Vivo Target Coverage Predictions.

Tiwari A, Luo H, Chen X, Singh P, Bhattacharya I, Jasper P, Tolsma JE, Jones HM, Zutshi A, Abraham AK.

CPT Pharmacometrics Syst Pharmacol. 2016 Oct;5(10):565-574. doi: 10.1002/psp4.12126. Epub 2016 Oct 22.

15.

The effect of celecoxib on tumor growth in ovarian cancer cells and a genetically engineered mouse model of serous ovarian cancer.

Suri A, Sheng X, Schuler KM, Zhong Y, Han X, Jones HM, Gehrig PA, Zhou C, Bae-Jump VL.

Oncotarget. 2016 Jun 28;7(26):39582-39594. doi: 10.18632/oncotarget.8659.

16.

A critical evaluation of venous thromboembolism risk assessment models used in patients with lower limb cast immobilisation.

Watson U, Hickey BA, Jones HM, Perera A.

Foot Ankle Surg. 2016 Sep;22(3):191-195. doi: 10.1016/j.fas.2015.08.003. Epub 2015 Sep 16. Erratum in: Foot Ankle Surg. 2018 Jun;24(3):268.

PMID:
27502229
17.

Buformin exhibits anti-proliferative and anti-invasive effects in endometrial cancer cells.

Kilgore J, Jackson AL, Clark LH, Guo H, Zhang L, Jones HM, Gilliam TP, Gehrig PA, Zhou C, Bae-Jump VL.

Am J Transl Res. 2016 Jun 15;8(6):2705-15. eCollection 2016.

18.

Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies.

Avery LB, Wang M, Kavosi MS, Joyce A, Kurz JC, Fan YY, Dowty ME, Zhang M, Zhang Y, Cheng A, Hua F, Jones HM, Neubert H, Polzer RJ, O'Hara DM.

MAbs. 2016 Aug-Sep;8(6):1064-78. doi: 10.1080/19420862.2016.1193660. Epub 2016 May 27.

19.

Fetal Alcohol Spectrum Disorders: Using Knowledge, Attitudes and Practice of Justice Professionals to Support their Educational Needs.

Mutch RC, Jones HM, Bower C, Watkins RE.

J Popul Ther Clin Pharmacol. 2016;23(1):e77-89. Epub 2016 Apr 22.

PMID:
27132254
20.

A mechanistic PK/PD model for two anti-IL13 antibodies explains the difference in total IL-13 accumulation observed in clinical studies.

Tiwari A, Kasaian M, Heatherington AC, Jones HM, Hua F.

MAbs. 2016 Jul;8(5):983-90. doi: 10.1080/19420862.2016.1172151. Epub 2016 Apr 6.

21.

Intrahospital Transport of the Critically Ill Adult: A Standardized Evaluation Plan.

Jones HM, Zychowicz ME, Champagne M, Thornlow DK.

Dimens Crit Care Nurs. 2016 May-Jun;35(3):133-46. doi: 10.1097/DCC.0000000000000176.

PMID:
27043399
22.

Clinical Micro-Dose Studies to Explore the Human Pharmacokinetics of Four Selective Inhibitors of Human Nav1.7 Voltage-Dependent Sodium Channels.

Jones HM, Butt RP, Webster RW, Gurrell I, Dzygiel P, Flanagan N, Fraier D, Hay T, Iavarone LE, Luckwell J, Pearce H, Phipps A, Segelbacher J, Speed B, Beaumont K.

Clin Pharmacokinet. 2016 Jul;55(7):875-887. doi: 10.1007/s40262-015-0365-0.

PMID:
26895021
23.

Development of a scale to evaluate midwives' beliefs about assessing alcohol use during pregnancy.

Watkins RE, Payne JM, Reibel T, Jones HM, Wilkins A, Mutch R, Bower C.

BMC Pregnancy Childbirth. 2015 Dec 30;15:353. doi: 10.1186/s12884-015-0779-6.

24.

Imidazopyridazine Inhibitors of Plasmodium falciparum Calcium-Dependent Protein Kinase 1 Also Target Cyclic GMP-Dependent Protein Kinase and Heat Shock Protein 90 To Kill the Parasite at Different Stages of Intracellular Development.

Green JL, Moon RW, Whalley D, Bowyer PW, Wallace C, Rochani A, Nageshan RK, Howell SA, Grainger M, Jones HM, Ansell KH, Chapman TM, Taylor DL, Osborne SA, Baker DA, Tatu U, Holder AA.

Antimicrob Agents Chemother. 2015 Dec 28;60(3):1464-75. doi: 10.1128/AAC.01748-15.

25.

Glutamine promotes ovarian cancer cell proliferation through the mTOR/S6 pathway.

Yuan L, Sheng X, Willson AK, Roque DR, Stine JE, Guo H, Jones HM, Zhou C, Bae-Jump VL.

Endocr Relat Cancer. 2015 Aug;22(4):577-91. doi: 10.1530/ERC-15-0192. Epub 2015 Jun 4.

26.

Inhibition of the ERCC1-XPF structure-specific endonuclease to overcome cancer chemoresistance.

McNeil EM, Astell KR, Ritchie AM, Shave S, Houston DR, Bakrania P, Jones HM, Khurana P, Wallace C, Chapman T, Wear MA, Walkinshaw MD, Saxty B, Melton DW.

DNA Repair (Amst). 2015 Jul;31:19-28. doi: 10.1016/j.dnarep.2015.04.002. Epub 2015 Apr 22.

PMID:
25956741
27.

Patient dependant on ventriculo-atrial shunt after 49 years.

Jones HM, Hussain R, Leach P.

Br J Neurosurg. 2015;29(4):587-8. doi: 10.3109/02688697.2015.1016893. Epub 2015 Mar 30.

PMID:
25822092
28.

Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective.

Jones HM, Chen Y, Gibson C, Heimbach T, Parrott N, Peters SA, Snoeys J, Upreti VV, Zheng M, Hall SD.

Clin Pharmacol Ther. 2015 Mar;97(3):247-62. doi: 10.1002/cpt.37. Epub 2015 Jan 9. Review.

PMID:
25670209
29.

Acute traumatic fracture dislocation of proximal tibiofibular joint: case report and literature review.

Ashraf MO, Jones HM, Kanvinde R.

Injury. 2015 Jul;46(7):1400-2. doi: 10.1016/j.injury.2015.01.026. Epub 2015 Jan 22. Review. No abstract available.

PMID:
25650267
30.

Evaluation of the anti-tumor effects of lactate dehydrogenase inhibitor galloflavin in endometrial cancer cells.

Han X, Sheng X, Jones HM, Jackson AL, Kilgore J, Stine JE, Schointuch MN, Zhou C, Bae-Jump VL.

J Hematol Oncol. 2015 Jan 29;8:2. doi: 10.1186/s13045-014-0097-x.

31.

Midwives' knowledge, attitudes and practice about alcohol exposure and the risk of fetal alcohol spectrum disorder.

Payne JM, Watkins RE, Jones HM, Reibel T, Mutch R, Wilkins A, Whitlock J, Bower C.

BMC Pregnancy Childbirth. 2014 Nov 5;14:377. doi: 10.1186/s12884-014-0377-z.

32.

The cytochrome P450 epoxygenase pathway regulates the hepatic inflammatory response in fatty liver disease.

Schuck RN, Zha W, Edin ML, Gruzdev A, Vendrov KC, Miller TM, Xu Z, Lih FB, DeGraff LM, Tomer KB, Jones HM, Makowski L, Huang L, Poloyac SM, Zeldin DC, Lee CR.

PLoS One. 2014 Oct 13;9(10):e110162. doi: 10.1371/journal.pone.0110162. eCollection 2014.

33.

The use of a five-hole pin clamp for removal of Hoffmann II(®) external fixation system.

Jones HM, Hickey BA.

Ann R Coll Surg Engl. 2014 Sep;96(6):485. doi: 10.1308/rcsann.2014.96.6.485. No abstract available.

34.

Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells.

Wang J, Ma X, Jones HM, Chan LL, Song F, Zhang W, Bae-Jump VL, Zhou C.

J Transl Med. 2014 Aug 21;12:226. doi: 10.1186/s12967-014-0226-x.

35.

Biochemical and antiparasitic properties of inhibitors of the Plasmodium falciparum calcium-dependent protein kinase PfCDPK1.

Ansell KH, Jones HM, Whalley D, Hearn A, Taylor DL, Patin EC, Chapman TM, Osborne SA, Wallace C, Birchall K, Large J, Bouloc N, Smiljanic-Hurley E, Clough B, Moon RW, Green JL, Holder AA.

Antimicrob Agents Chemother. 2014 Oct;58(10):6032-43. doi: 10.1128/AAC.02959-14. Epub 2014 Jul 28.

36.

Fetal alcohol spectrum disorder: development of consensus referral criteria for specialist diagnostic assessment in Australia.

Watkins RE, Elliott EJ, Wilkins A, Latimer J, Halliday J, Fitzpatrick JP, Mutch RC, O'Leary CM, Burns L, McKenzie A, Jones HM, Payne JM, D'Antoine H, Miers S, Russell E, Hayes L, Carter M, Bower C.

BMC Pediatr. 2014 Jul 8;14:178. doi: 10.1186/1471-2431-14-178.

37.

Is distal screw entry point associated with subtrochanteric fracture after intracapsular hip fracture fixation?

Hickey B, Jones HM, Jones S.

ANZ J Surg. 2014 Apr;84(4):245-8. doi: 10.1111/ans.12498.

PMID:
24812708
38.

Optimization of an imidazopyridazine series of inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1).

Chapman TM, Osborne SA, Wallace C, Birchall K, Bouloc N, Jones HM, Ansell KH, Taylor DL, Clough B, Green JL, Holder AA.

J Med Chem. 2014 Apr 24;57(8):3570-87. doi: 10.1021/jm500342d. Epub 2014 Apr 11.

39.

Systems pharmacology of the nerve growth factor pathway: use of a systems biology model for the identification of key drug targets using sensitivity analysis and the integration of physiology and pharmacology.

Benson N, Matsuura T, Smirnov S, Demin O, Jones HM, Dua P, van der Graaf PH.

Interface Focus. 2013 Apr 6;3(2):20120071. doi: 10.1098/rsfs.2012.0071.

40.

Recommendations from a consensus development workshop on the diagnosis of fetal alcohol spectrum disorders in Australia.

Watkins RE, Elliott EJ, Wilkins A, Mutch RC, Fitzpatrick JP, Payne JM, O'Leary CM, Jones HM, Latimer J, Hayes L, Halliday J, D'Antoine H, Miers S, Russell E, Burns L, McKenzie A, Peadon E, Carter M, Bower C.

BMC Pediatr. 2013 Oct 2;13:156. doi: 10.1186/1471-2431-13-156.

41.

Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): Preparation and evaluation of pyrazole linked analogues.

Large JM, Osborne SA, Smiljanic-Hurley E, Ansell KH, Jones HM, Taylor DL, Clough B, Green JL, Holder AA.

Bioorg Med Chem Lett. 2013 Nov 1;23(21):6019-24. doi: 10.1016/j.bmcl.2013.08.010. Epub 2013 Aug 11. Erratum in: Bioorg Med Chem Lett. 2014 Jan 1;24(1):397.

42.

Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development.

Jones H, Rowland-Yeo K.

CPT Pharmacometrics Syst Pharmacol. 2013 Aug 14;2:e63. doi: 10.1038/psp.2013.41. No abstract available.

43.

Involving consumers and the community in the development of a diagnostic instrument for fetal alcohol spectrum disorders in Australia.

Jones HM, McKenzie A, Miers S, Russell E, Watkins RE, Payne JM, Hayes L, Carter M, D'Antoine H, Latimer J, Wilkins A, Mutch RC, Burns L, Fitzpatrick JP, Halliday J, O'Leary CM, Peadon E, Elliott EJ, Bower C.

Health Res Policy Syst. 2013 Jul 30;11:26. doi: 10.1186/1478-4505-11-26.

44.

Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1).

Chapman TM, Osborne SA, Bouloc N, Large JM, Wallace C, Birchall K, Ansell KH, Jones HM, Taylor D, Clough B, Green JL, Holder AA.

Bioorg Med Chem Lett. 2013 May 15;23(10):3064-9. doi: 10.1016/j.bmcl.2013.03.017. Epub 2013 Mar 21.

45.

Predicting pharmacokinetic profiles using in silico derived parameters.

Hosea NA, Jones HM.

Mol Pharm. 2013 Apr 1;10(4):1207-15. doi: 10.1021/mp300482w. Epub 2013 Mar 7.

PMID:
23427934
46.

A modified Delphi study of screening for fetal alcohol spectrum disorders in Australia.

Watkins RE, Elliott EJ, Halliday J, O'Leary CM, D'Antoine H, Russell E, Hayes L, Peadon E, Wilkins A, Jones HM, McKenzie A, Miers S, Burns L, Mutch RC, Payne JM, Fitzpatrick JP, Carter M, Latimer J, Bower C.

BMC Pediatr. 2013 Jan 25;13:13. doi: 10.1186/1471-2431-13-13.

47.

Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond.

Barton HA, Lai Y, Goosen TC, Jones HM, El-Kattan AF, Gosset JR, Lin J, Varma MV.

Expert Opin Drug Metab Toxicol. 2013 Apr;9(4):459-72. doi: 10.1517/17425255.2013.759210. Epub 2013 Jan 21. Review.

PMID:
23331046
48.

Dose selection based on physiologically based pharmacokinetic (PBPK) approaches.

Jones HM, Mayawala K, Poulin P.

AAPS J. 2013 Apr;15(2):377-87. doi: 10.1208/s12248-012-9446-2. Epub 2012 Dec 27. Review.

49.

A mathematical model of the human menstrual cycle for the administration of GnRH analogues.

Röblitz S, Stötzel C, Deuflhard P, Jones HM, Azulay DO, van der Graaf PH, Martin SW.

J Theor Biol. 2013 Mar 21;321:8-27. doi: 10.1016/j.jtbi.2012.11.020. Epub 2012 Dec 1.

PMID:
23206386
50.

Consensus diagnostic criteria for fetal alcohol spectrum disorders in Australia: a modified Delphi study.

Watkins RE, Elliott EJ, Mutch RC, Payne JM, Jones HM, Latimer J, Russell E, Fitzpatrick JP, Hayes L, Burns L, Halliday J, D'Antoine HA, Wilkins A, Peadon E, Miers S, Carter M, O'Leary CM, McKenzie A, Bower C.

BMJ Open. 2012 Oct 25;2(5). pii: e001918. doi: 10.1136/bmjopen-2012-001918. Print 2012.

Supplemental Content

Loading ...
Support Center